New combo therapy shows promise for rare blood cancers
NCT ID NCT07318662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding venetoclax to standard chemotherapy (HMAs) works better than chemotherapy alone for people newly diagnosed with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 224 adults are being observed to see how many respond to treatment and how long they live. The goal is to find a more effective way to control these blood cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Frailty check may steer safer cancer care for seniors
- Can a different immune drug cut viral infections after stem cell transplants?
- Supercharged donor cells aim to stop leukemia return after transplant
- Worldwide data pool could pave the way for mitochondrial disease trials
- New blood test may predict cancer relapse after transplant
- New drug cocktail aims to boost transplant success in tough leukemias